|Contents of Shopping Cart|
Ubrelvy (Ubrogepant) is indicated for the treatment of:
c. Diabetes mellitus
e. Generalized anxiety
Answer: (b) Ubrelvy (Ubrogepant) is indicated for the acute treatment of migraine with or without aura in adults. It is the first and only orally-administered calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) for the treatment of migraine attacks once they start.
Ubrelvy (Ubrogepant) provided lasting relief up to 24 hours as well. It works in a new way by blocking CGRP, a protein that is released during a migraine attack, from binding to its receptors. It works without constricting blood vessels, which some older treatments are known to do. It is non-narcotic, not scheduled, and does not have addiction potential. It has been approved with two dose strengths, 50 mg and 100 mg.
The recommended dose is 50 to 100 mg by mouth for acute migraine. If needed, a patient may take second dose at least 2 hr after initial dose. Do not exceed 200 mg within 24 hours.
Safety of treating greater than 8 migraines/30-day period is not established.
Nausea, somnolence and dry mouth are currently reported side effects of the drug.
Try our Naplex QBank. www.pharmacyexam.com **Please note: This type of question will not show up in an MPJE. We are just posting to MPJE group for knowledge.